Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That is actually just the press release about the study, but the point is the same. Promising. The press doesn't hurt. AMD affects just about everyone eventually. Not a bad thing to be involved in. Definitely promising, but lets not get too far ahead of ourselves. I wouldn't be surprised if the call tomorrow is essentially a verbal PR. Regardless, People are starting to talk about Fuse. That is definitely a good thing.
Just reading the abstract, it doesn't look like they actually found anything new except that Beta carotene may increase risk for lung cancer in former smokers. It looks like it just validates the formula that Macular Health has been using for about a decade.
Quote from the NEI about what the study means:
"Adding omega-3 fatty acids did not improve a combination of nutritional supplements commonly recommended for treating age-related macular degeneration (AMD), a major cause of vision loss among older Americans, according to a study from the National Institutes of Health (NIH). The plant-derived antioxidants lutein and zeaxanthin also had no overall effect on AMD when added to the combination; however, they were safer than the related antioxidant beta-carotene, according to the study published online today in the Journal of the American Medical Association."
Still not a bad group to be partnered with.
good point.
itd be tough to partner with a company that goes under because it can't raise enough money...
apparently the Mayans were off by about 5 months.
at least half are written by investors.
Lonza bought Cambrex in 2007
i believe Bay was just responding to your incorrect assumption.
Woods is all about his legacy. It isn't about money. Never was. Although being the first billion dollar athlete doesn't exactly hurt that.
yup. that was pretty much the point of my post. check the links.
Wrong sir.
http://web.tigerwoodsfoundation.org/aboutTWF/whatWeDo
http://www.huffingtonpost.com/katherine-gustafson/tiger-woods-what-happens_b_424066.html
http://philanthropy.com/blogs/philanthropytoday/tiger-woods-expands-foundation-to-washington-area/24671
Say what you will about the choices he has made in his personal life (or anyone else's for that matter). His professional and philanthropic records are exemplary. Don't hate on the man for being one of the few professional athletes who grinds on his craft and actually makes the most of his situation on and off the field of play.
Really? Because supporting a badass who is raising awareness for kids that need medical care while also giving a one finger salute to sexism is a bad thing? Too bad all pump and dumps dont do that.
how are they going to knock on doors if they are in their garage?
you do know you only lose money if the price goes down after the R/S, right?
yea. dont buy this stock. nothing will be coming of it. there are already better apps out there and there is no way in hell they will get the method patent they need to have any hope of being profitable.
wow. people actually fight to be the first person to like the photo? shouldn't those kids be in school?
BG, when fuse runs a bit I will send you one of those red dresses and a pack of powerfuse.
oh yea, and also they have no problem diluting to raise money.
Phase 2 in Israel. Partnered with MGH and Mayo clinic in the US (two of the best research institutions in the world) to start a phase 2 trial here in the 3rd quarter. Compassionate use on a rabbi in Israel worked well (...he is still alive). Company recently got a new CEO whose compensation is basically based on getting the company uplisted. a 10:1 or 20:1 reverse split was approved at the shareholder meeting in April. Most likely this thing pops up to above .25 cents and they reverse split it to gain eligibility for Nasdaq. The have orphan drug status from the FDA because ALS is a rare disease, so they would have a few years of protected profits, and just about any treatment would be better than the current BS which extends life by about 6 months and costs thousands of dollars per year. Other than that, the share price bounces between about .20 and .25 cents.
Speculations: They are probably looking at about a year or two of trials in the US, depending on how well it works. I would say phase two finishes in the 2nd 3rd quarter of 2014, results published during the 4th quarter. They have no problem getting funding from Israel, and working with MGH/Mayo should lead to plenty of other funding avenues. Following a successful phase 2 and securing the necessary funding, Phase 3 sometime late in 2014 or early 2015, finishing up probably 12 months after that.
Basically, it is not a great stock to flip. The price really hasn't moved much below .20 or much above .25. there were a couple hits down to about 17, and a couple up to around 30, but the price is pretty damn stable for a penny stock. Should be a decent company to hold. A reverse split here would not be a sign of desperation, but would be a way to get institutional investors on board which requires a share price of over a couple bucks. Not a short term play, but decent long term prospects.
it works. 10 years of research show that.
agreed. then again, with a price of 3-4 cents, any news could push it up towards where it belongs (~.15)
this is true. one of them is a joke. if Fuse can survive the possibilities are pretty endless.
and I have plans of developing clean, renewable energy that runs hopes and dreams.
no revenues from a compassionate use approval, but it would bode well for the treatment in general. May not create much of a jump in pps though.
excellent questions. it was a rather large drop, and only half a million shares.
it sounds like they won't be done administering the treatment for 90 days. after that they take the 3,6,9, and 12 month measurements.
they already did. http://www.nasdaq.com/symbol/bhrt/sec-filings
Why the 15th?
the internet doesn't count?
Welp, I take back allllll my posts from two days ago.
a great idea. I will also probably add another chunk of shares this week, and then see what the 10-Q says. However, I do not think it will be all that eye-catching since revenue is really not an option at this point.
i have only been looking into it for a couple weeks, but it seems like the company and its board are going about things in a patient manner. They know their interventions will help people. Why the stock is stuck around 3-4 cents? I really do not know. There are plenty of other biotech companies with much higher prices, and not nearly the same potential. Reading through their studies and having sat through the webinar, it is clear the people running this company know what they are talking about and what they are doing, and that is EXTREMELY rare in any company stuck in pinky land.
I do know they went public at a bad time, and have had trouble getting the funds necessary to run their trials, but that time seems to be over. They work with renowned physicians at well respected medical centers, and the results have all been positive. At the very least this should be at 20 cents right now.
maybe its just resignation, but i am starting to appreciate the wide range of partners.
it (or more likely they since there are 3 ongoing trials) will be successful. its just a matter of time.
hopefully. Facebook is not the place to vent about your sleepless nights as an investor. Nobody looking to buy the product wants to see people whining.
they do 3, 6, 12 month followups. So, about a year. new ones have an added gene (SDF-1) that increases helps increase bloodflow to the area.
myoheart (old version): works. running stage 2 trials.
myoheart (new version): works, but have to start back at stage 1.
adipose stem cells: works, working in mexico on trials.
bio/biotech firms dont get points for promising results much anymore. they need to show they have a product that is going to make them money.
on the financial front: they will release the 10-Q before May 15 due date.
on the science front: myoheart SDF-1 is better than the original because it helps increase blood flow in the area, but has to start back at phase 1 with it.
used stem cells from fat to increase development of blood flow. has worked very well in patients with lower limb ischemia (common in diabetes). pretty remarkable really. plenty of nasty pictures. this one is a point of care kit, so no need to send away to the lab.
just going through all their study data.
they do not ask for your credit card. all they need is a name and an email address.
ah disc, i have been critical of Fuse when it is warranted, and the pattern of bad news for shareholders+less than earth shattering PR has grown old. Not that I would wish this on anyone with a life, and so I do not actually suggest you do it, but in general my posts are positive and supportive of the approach Fuse has taken. Should you find yourself extremely bored, go back a year and you will find posts I have written stating that a solid social media marketing campaign is what will make or break this company, regardless of how good the products actually are (that was before the drops had even been released). The fact that the products actually work is a bonus if the marketing is done correctly.
My only consistant knock has been Adler's involvement, and I have even given him credit in the past for his ambition. However, there are people in the company better suited to be making public statements than he is.